Innovation Horizons | Gregory Downing
3
archive,author,author-gjdowning,author-3,ajax_fade,page_not_loaded,,qode-theme-ver-10.1.1,wpb-js-composer js-comp-ver-6.5.0,vc_responsive

Author: Gregory Downing

We know that specialty drugs( most injectables, biologics, and drugs requiring specialized administration) are expensive but spending on specialty drugs has often been difficult to measure because of proprietary rebate payments by manufacturers to insurers, pharmacy benefit managers, and state Medicaid agencies. A recent analysis...